Characterizing the Predictive Value of Cyclin E1 Protein Expression to a WEE1 Inhibitor, Azenosertib (ZN-c3)
Time: 2:00 pm
day: Day Two Track A
Details:
- CCNE1 gene amplification is a prevalent oncogenic driver in high grade serous ovarian cancer (HGSOC) and is associated with platinum resistance and poor patient outcomes. Importantly, Cyclin E1 overexpression can also occur in both the presence and absence of gene amplification
- Increased levels of Cyclin E1 results in accumulation of replication stress markers and showed greater antitumor effects in Cyclin E1high ovarian cancer models than Cyclin E1low models in vitro and in vivo
- Cyclin E1 positive status is highly prevalent in HGSOC patients with no CCNE1 amplification, and shows promising trends as a predictive biomarker for patients treated in a study of azenosertib in combination with chemotherapy
